Mycophenolate mofetil treatment in resistant myositis

Area of Science:

• Rheumatology
• Immunology
• Neurology

Background:

• Myositis is a group of rare chronic inflammatory diseases affecting muscles.
• Conventional immunosuppressive therapies often fail to achieve remission in some myositis patients.
• Identifying effective alternative treatments for refractory myositis is crucial.

Purpose of the Study:

• To evaluate the efficacy and tolerability of mycophenolate mofetil (MMF) in patients with myositis.
• To assess MMF's impact on muscle strength, creatine kinase (CK) levels, and steroid requirements.
• To determine if MMF is a viable option for myositis refractory to standard treatments.

Main Methods:

• A retrospective review of six patients diagnosed with myositis who were refractory to conventional immunosuppressive therapy.
• Efficacy assessment included monitoring changes in muscle strength, serum creatine kinase (CK) levels, and daily prednisolone dosage.
• Patients received MMF for a mean duration of 22.3 months at a mean daily dose of 1.6 g.

Main Results:

• All six patients (100%) were female and Caucasian, with a mean age of 49.8 years.
• Patients had previously failed a median of three different immunosuppressive drugs.
• Significant reductions were observed in both prednisolone dose (from 13.7 to 8.5 mg/day, P=0.03) and CK levels (from 2395 to 746.6 IU/l, P=0.03).

Conclusions:

• Mycophenolate mofetil (MMF) demonstrates potential efficacy in managing myositis cases that are unresponsive to conventional immunosuppressive drugs.
• MMF may offer a beneficial treatment option for patients with refractory myositis, improving key clinical and biochemical markers.
• Further research with larger cohorts is warranted to confirm these findings and establish MMF's role in myositis treatment.